Want to see IN:VALIANTLAB full AI Analyst Report?
Top Page
Valiant Laboratories Ltd.
(VALIANTLAB)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹107.00
▲(45.58% Upside)
Action:Reiterated
Date:08/18/26
The score is primarily constrained by weak financial performance: losses and sharply deteriorated cash flow (negative operating cash flow and deeply negative free cash flow) outweigh the FY2026 revenue rebound and modest leverage. Technicals are supportive due to a strong uptrend versus moving averages, but overbought signals increase near-term risk. Valuation is a modest headwind with a relatively high P/E and no dividend yield provided.
Positive Factors
FY2026 Revenue Rebound
The FY2026 revenue recovery indicates that demand and sales execution improved after two weak years. If maintained, renewed top-line scale can improve capacity utilization, support fixed-cost absorption, and provide a foundation for restoring profitability across the API portfolio.
Negative Factors
Persistent Losses
The shift from earlier profits to losses shows that the current operating model is not converting revenue into sustainable shareholder returns. Continued losses could weaken internal funding capacity, limit reinvestment, and make the FY2026 revenue rebound less valuable unless margins recover.
Read all positive and negative factors
Positive Factors
Negative Factors
FY2026 Revenue Rebound
The FY2026 revenue recovery indicates that demand and sales execution improved after two weak years. If maintained, renewed top-line scale can improve capacity utilization, support fixed-cost absorption, and provide a foundation for restoring profitability across the API portfolio.
Read all positive factors
Valiant Laboratories Ltd. (VALIANTLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹5.83B
Dividend YieldN/A
Average Volume (3M)39.85K
Price to Earnings (P/E)35.9
Beta (1Y)0.53
Revenue Growth89.64%
EPS Growth10627.64%
CountryIN
Employees84
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.55
Shares Outstanding54,312,500
10 Day Avg. Volume36,599
30 Day Avg. Volume39,851
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Valiant Laboratories Ltd. Business Overview & Revenue Model
Company Description
Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in va...
How the Company Makes Money
Valiant Laboratories Ltd. makes money primarily by manufacturing and selling active pharmaceutical ingredients (APIs) to customers in the pharmaceutical supply chain (such as finished-dosage manufacturers and formulators). Its core revenue stream ...
Valiant Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
71
Positive
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.37B | 1.39B | 1.82B | 3.34B | 2.92B |
| Gross Profit | 272.66M | 222.17M | 115.76M | 565.90M | 523.21M |
| EBITDA | 87.11M | 7.55M | -85.98M | 399.53M | 442.67M |
| Net Income | -32.68M | -22.01M | 3.20M | 289.98M | 274.96M |
Balance Sheet | |||||
| Total Assets | 4.64B | 4.01B | 3.43B | 2.13B | 1.82B |
| Cash, Cash Equivalents and Short-Term Investments | 331.50M | 759.91M | 1.44B | 353.61M | 205.33M |
| Total Debt | 462.12M | 1.22B | 767.08M | 602.17M | 611.26M |
| Total Liabilities | 1.53B | 1.67B | 1.06B | 1.12B | 1.10B |
| Stockholders Equity | 3.11B | 2.34B | 2.37B | 1.00B | 714.60M |
Cash Flow | |||||
| Free Cash Flow | -471.97M | -1.13B | -439.85M | 183.70M | -46.25M |
| Operating Cash Flow | -129.97M | 13.13M | 18.85M | 560.51M | 22.51M |
| Investing Cash Flow | 72.52M | -527.68M | -1.44B | -551.68M | -122.38M |
| Financing Cash Flow | 43.57M | 446.53M | 1.52B | -9.34M | 61.81M |
Valiant Laboratories Ltd. Technical Analysis
Positive
73.50
Price Trends
74.80
Positive
74.39
Positive
68.80
Positive
Market Momentum
8.64
Negative
71.27
Negative
54.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VALIANTLAB, the sentiment is Positive. The current price of 73.5 is below the 20-day moving average (MA) of 92.62, below the 50-day MA of 74.80, and above the 200-day MA of 68.80, indicating a bullish trend. The MACD of 8.64 indicates Negative momentum. The RSI at 71.27 is Negative, neither overbought nor oversold. The STOCH value of 54.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VALIANTLAB.
Valiant Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | ₹7.02B | 89.92 | ― | 1.93% | -3.14% | -5.80% | |
58 Neutral | ₹3.30B | 23.66 | ― | ― | 49.96% | 33.70% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹4.90B | 22.00 | ― | 0.58% | 11.43% | 258.53% | |
52 Neutral | ₹3.67B | 33.93 | ― | 0.37% | 24.66% | 10.89% | |
50 Neutral | ₹6.74B | 152.74 | ― | 0.15% | 7.55% | -57.19% | |
49 Neutral | ₹5.83B | 35.92 | ― | ― | 89.64% | 10627.64% |
* General Sector Average
IN:VALIANTLAB
Valiant Laboratories Ltd.
107.27
23.47
28.01%
IN:ALBERTDAVD
Albert David Ltd
858.35
60.89
7.64%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
296.60
196.70
196.90%
IN:MEDICAMEQ
Medicamen Biotech Limited
270.55
-76.46
-22.03%
IN:MEDICO
Medico Remedies Ltd.
39.79
0.63
1.61%
IN:ZIMLAB
Zim Laboratories Ltd.
125.55
50.16
66.53%
Valiant Laboratories Ltd. Corporate Events
Valiant Laboratories to Hold 5th AGM via Video Conferencing with Full E-Voting Access
Aug 31, 2026
Valiant Laboratories Ltd., a Mumbai-based listed pharmaceutical and chemical manufacturer, engages with a broad shareholder base through India’s main stock exchanges. The company’s operations are shaped by stringent regulatory requirem...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.